Entering text into the input field will update the search result below

Gilead launches early-stage study of inhaled remdesivir

Jul. 08, 2020 3:23 PM ETGilead Sciences, Inc. (GILD)GILDBy: Douglas W. House, SA News Editor36 Comments
  • Gilead Sciences (GILD -1.1%) has initiated a U.S. Phase 1a clinical trial evaluating an inhalable formulation of antiviral remdesivir in 60 healthy volunteers between the ages of 18 and 45.
  • The company says an inhalable version may enable more targeted and accessible administration in non-hospitalized COVID-19 patients and lower systemic exposure to the drug.
  • The intravenous formulation remains the only medicine approved in the U.S. for emergency use in hospitalized patients, receiving the FDA nod on May 1.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.